“…Reliability of conventional treatment strategies to treat cancer patients is losing pace every day, hence, designing a safe and cost‐effective treatment strategy has become a priority to reduce disease allied deaths globally (Kelak et al, 2018). To overcome the above‐highlighted hurdles, numerous surface engineered tinny sized “nanomedicines” such as plasmonic gold nanoparticles, polymeric nanospheres, graphene oxide sheets, porous silica particles, gold‐silica hybrid structures, drug conjugated self‐assemblies, and so forth have been proposed for cancer imaging and therapeutic applications (Chauhan et al, 2019; Gonçalves et al, 2020; Lerra et al, 2019; Li Volsi et al, 2017; Mehta et al, 2021; Ren et al, 2020; Selvaraj et al, 2018; Y. Wang, Wang, et al, 2018; Wen et al, 2021). However, sophisticated synthesis and surface engineering, low cargo capacity, slow biodegradation, poor biocompatibility, lack of site‐selective drug delivery response, easy absorption of protein molecules on their surface during blood circulation, major accumulation in liver and spleen, low penetration, and retention ability in tumor environment are critical obstacles of these nanostructures (Bailly et al, 2019; Cai & Chen, 2019; Chinen et al, 2017; Farjadian et al, 2019; Kramer et al, 2017; J.‐Y.…”